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The influence of excitatory amino acids (EAA) on growth honnone (OH) secretion and the 
possible site of action was in ...estigated in the pig. In Experiment (Exp) I three replicates were 
cond ucted with 30 prepuberal gilts, 130 d of age and a"'e raging 70.6 ± 1.3 kg body weight (8W). 
Six gi lts each reeei ...ed intra ...enously (i ... ) 0 , 50, 100, or ISO mglkg BW of aspartate (ASP) or 
glutamate (OLU) in saline. Blood samples were collectcd e ...cry IS min for 2 hr before and 3 hr after 
treatmcnt. In Exp II. mature o ...arieetomized gilts (1 63 ± 10 kg BW) lIIat had been immunizcd 
against growth honnone releasing factor (ORF) conjugated to human serum albumin (GRFi: n = 4) 
or against human serum albumin alone (HSAi; n '" 5) received ISO mglkg RW ASP or OLU i ... in 
a 2 x 2 factorial arrangement of treatments. which was then repeated in a crosso ...er design. One 
week later. all animals recei ...ed 10 mglkg N-methyl-D,L.aspanatc (NMA: EAA agonist) in saline i .... 
Blood samples wcre collected as described abo ... e. In Exp III. cultures of anterior pitui tary cells from 
market-weight (a...eraging 105 kg BW) gilts were studied. On Day 4 of culture. cells ( IO' seeded! 
8well) were challenged with 10- , 10-6. or 10-4 M ASP or OLU, IO-{. M [Ala"l·human ORF 
{1 - 29)-N H2' or the EAA antagonist, 2-am ino-5.phosphonopentanoic acid (1 0-4 M; AP5), alone or 
in combination with ASP or OLU. In Exp I, al l doses of ASP and lIIe 100- and I 50-mg doses ofGLU 
increased (P < 0.05) OH secretion whcn compared with Time O. However. seru m GH concentrations 
were high!::r (P < 0.0 1) after ISO mg/kg of AS P when compared with those after 150 mglkg of GLU. 
In Exp 11 , serum GH concentrations increased (P < 0.05) in HSAi but not in ORFi pigs (a ...eraging 
1.2 ±0.2 nglml before and 8.2:t 0.7, 6.3 ±0.5, and 9.2 ± 0.5 nglml by 15 min after ASP, OlU, and 
NMA, respect i ...ely). In Exp Ill . re lati ...c to controls (40 ± 6 nglml). GH increased (P < 0.05) 1.6·, 
81.9-. and 1.9-fol d and 1.7-, 1.8·, and 2.0-fold after 10- , 10-1>, and 10--' M ASP and GLU. respec­
ti ...ely. The BAA receptor a",agonist AP5 failed to prevent the OH response to ASP or OLU. except 
for 10-8 M ASP. In summary. ASP is a more potent secre tagogue of OH secretion than is OLU in 
... i...o, whereas each is equipotent in ...it ro. Because no stimulation of GH by EAA was obser ...ed in 
GR Fi pigs and no speci fic dose.response effect or EAA was found in ... itro. it may be concluded that 
modulation by EAA is mediated pri marily at the le ...e1 of the hypo thalamus or higher brain centers. 
INTRODUCTION 
Excitatory amino acids (EAA), including glutamate (GLU) and aspartate (ASP), have 
been implicated as major neurotransmitte rs in the mam malian cenlra l nervous system 
(eNS) (I). Price e t al. (2) demo nstrated the preferentia l uptake of exogenously adminis+ 
te red AS P and GLU by the c ircumvenlricular organs of the rat bra in, including the arcuate 
nucleus. The syste mic inj ectio n of GLU increased GLU levcls foutfold in the median 
eminence, but nOI in other arcas of the hypothalamus in mice (3). N-Mcthyl-D,L-asparatc 
(NMA), a potent agonist of ASP and GLU, stimulates the re lease of pituitary honnones. 
including lute inizi ng hormone (LH) (4-6) and growth honnone (GH) (4,7.8). NMA stim­
ulated GH secretion and accelerated growth in prepuberal monkeys (5) and dramatically 
increased serum concentrations of GH in wethers (7) and ovariectomized ewes (8). In the 
pig, NMA increased GH secretion without regard to steroid milieu (9). In contrast, the 
NMA stimulation of GH secretion from pig pituitary cells in vi tro was influenced by the 
reproductive state of the pituitary donor ( 10). There is limited informalion on the influence 
of GLV and ASP on GH secretion in Ihe pig. The objective of this study was to I) 
detennine the effect of GLU and ASP on GH secretion and 2) determine if the action of 
GLU and ASP appears to be directly on the pituitary and/or brain to mod ulate GH 
secretion. 
MATERIALS AND METHODS 
Experiment I. The experimental protocols were approved by the Institutional Animal 
Care and Use Committee. Founeen prepuberal gilts (Yorkshire x Landrace x Hampshire). 
130 d of age and averaging 70.6 ± 1.3 kg body weight (BW). received 0 (control), 50. 100, 
or 150 mglkg BW of ASP2 or GLU2 in saline intravenously (iv). One week later, the 
experiment was replicated with pigs reassigned to treatment such that no pig received the 
same dose as before, resulting in four pigs/dose of ASP. GLU, or ~alin e. A third replicate 
was conducted with an additional 16 prepuberal gi lts of the same genetic base, 130 d of 
age and averaging 70. 1 ± 1. 1 kg BW. Two gilts each received either ASP or GLU al the 
doses described above. while four pigs acted as contro ls and received 0.9% saline iv. Thi s 
resulted in six pigs/dose of ASP or GLU and eight control pigs across repl icates. A 
cannula was placed in the jugular vein of all pigs the day before treatment. On the day of 
treatment. blood was col1ected cvcry 15 min for 2 hr before and 3 hr after treatment. 
Serum was harvested and stored at - 20" C until assayed for GH by radioimmunoassay 
(RIA). 
Experiment II. Mature ovariectomized pigs (Yorkshire x Hampshire; 163 ± 10 kg BW) 
1010 12 months of age that had been immunized against growth honnone releasing factor 
(GRF) (l·29)-(GlY).rCys-NH2 conjugated to human serum albumin (G RFi ; n == 4) or 
against human serum albumin alone (HSAi: n == 5). as previously described (I I), received 
ISO mglkg BW ASP or GLU iv in a 2 x 2 factorial arrangement of treatments, which was 
repeated 24 hr later in a crossover design. One week later. all pigs were treated with NMA 
(10 mglkg BW) in saline iv. Blood samples were collected via a jugular vein cannula 
every 15 min for 2 hr before and 3 hr aft er treatment. and serum was handled as described 
in Exp I and assayed for GH. Antibody tilers against GRF were determined as described 
below. 
Experiment III. Two replicates were conducted with 12 and 6 pituitary glands per 
replicate, respecti vely. Pituitary glands were aseptically removed from cross-bred (York­
shire x Landrace x Hamp~hire) gilts weighing approximately 105 kg and 180 d of age at 
slaughter. Ovaries were examined at slaughter, and giltS were considered prepuberal. 
because their ovaries were devoid o r corpora a lbicantia and corpora lutea. All subsequent 
procedurcs were pcriormed under sterile conditions. The anterior lobe was di ssccted from 
each pituitary gland, and cells were enzymaticall y dispersed and cultured as previou>;ly 
described ( 12, 13). To summari ze the culture methods, after cells were dispersed and 
centrifuged. the cell pellet was resuspended in growth medium (Oul becco'>; modified 
Eagle ' s medium LOME] , Ham 's nutrient mixt ure F-12 [F. 12])2 90% (vol/vol ; 4,500 mg/I 
glucose ], and 10% Ivol/voll Filion-Jackson medium IBGjb]J containing 2 mg/ml of bo­
vine serum albumin, 10 mM N-hydroxyethylpipemzine-N"-2-ethane~ulfonic acid [pH 7.21, 
100 Ulml of penicillin, 250 ng/ml of amphotericin B,2 and 100 ~g/ml of ~treptomycin to 
which was added 2% [vol/vail fetal bovine serum)? which wa~ supplemented with 100 
ng/ml of cortisol, 1.0 ng/ml of human insulin, 10 ~g/ml of human transferrin,2 10 pg/ml 
of glucagon, 100 pg/ml of human insulin, 10 ~glml of human transferrin,2 10 pglml of 
glucagon, 100 pglml of epidermal growth factor, 200 pg/ml of bovine parathyroid hor­
mone, 400 pglml of triiodothyronine,2 and 200 pg/ml of fibrobla~t growth factor. 4 Cell 
viability and number were assessed by counting the number of cells excluding trypan blue 
on a hemocytometer. Culture medium was changed on Day 3 (day of seeding = Day 0 of 
culture) and replaced with serum-free growth medium as described before, except with 
DME containing 1,000 mg of glucose/l.2 On Day 4 of culture, medium was discarded, 
plates were rinsed twice with serum-free medium. and pituitary cells (lOs cells/well) were 
cultured in I ml of fresh medium without serum. Cells were challenged with 1O-t> M 
synthetic GRF ([Ala 1s]-hGRF(I-29)-NH2i, ASP or GLU (10-8 , 10-6 or 10-4 M), or 
2-amino-5-phosphonopentanoic acid (AP5; 10-4 M) alone or in combination with ASP or 
GLU. The dose of GRF and AP5 used was based on previous observations (10). Cells 
were exposed to treatment for 4 hr, at which time medium wa~ harve~ted and quantified 
for GH. Therc were three to ~even wells per treatment per replicate. 
Hormone Assays. Antibody titers against GRF were determined by incubating various 
dilutions of serum with [12SI]GRF(l-44)-NH2. The antibody titer was expressed as the 
initial dilution of serum from GRFi gilts required to bind 30% [12SIJGRF or percent 
binding at a dilution of I: 100 in HSAi gilts. On Day I. 0.25 ml of diluted serum, 0.15 ml 
of assay buffer (0.1 M acetate buffer; pH 5.6), and 0.1 ml of [mI]GRF (8,000 to 10,000 
cpm in assay buffer) were aliquoted into glass 12 x 75 tubes, vortexed, and incubated for 
24 hr at 40 C. Nonspecific binding was determined by incubating 0.4 ml of assay buffer 
with 0.1 ml of ,1 2SI]GRF. Nonspecific binding was les~ than 5%. On Day 2, 0.2 ml of 
rabbit anti-pig gamma globulin (I: 10 in assay buffer) and 0.5 ml of6% polyethyleneglycol 
in assay buffer were add to all tubes, mixed, and centrifuged at 2,000 x g for 15 min to 
separate bound and free [ 1251]GRF. The supernatant was decanted, and the radioactivity in 
the remaining pellet was counted. 
Radioiodination ofGRF. An aliquot of 5 ~g of GRF2 in 5 ~I of 0.01 M acetic acid was 
iodinated by the chloramine-T method (14). Ten microliters of 0.5 M phosphate buffer 
(pH 7.5) was added to the reaction vial contai ning the GRF, and 10 ~I of 0.05 M phosphate 
buffer (pH 7.5) was added to the vial containing I mCi of [125I1Na, resulting in a total 
volume of 20 11l. One half of the r12SI]Na in 10 111 was added to the reaction vial, and I 
~g of chloramine-T (I ~gl2 ~I of 0.05 M phosphate buffer; pH 7.5) was mixed with GRF 
and [1 25l[Na for 20 s. The reaction was stopped with 2.5 ~g of sodium metabi sulfate (2.5 
J-Ig/5 ~l of 0.05 M phosphate buffer; pH 7.5) added to the reaction mixture for 30 s. The 
reaction mixture was diluted with 100 J-II of 0.1 % gelatin in 0.1 M acetic acid and was 
layered on a 10 x I cm Biogel P_46 column to separate free IlS I from [ 1<!sl]G RF. 
Serum concentrations of GH were quantified by RIA (15). The assay sensitivity was 0.4 
nglml. Intraassay and interassay coeffi cients of variation were 3.2% and 13.6%, respec­
tively. 
Statistical Analysis. To determine the effect of ASP and GLU on GH secretion in Exp 
I, data were subjected to the general linear model split plot-in-time analysis of variance 
(ANOVA) procedure of the Statistical Analysis System (SAS: 16). The statistical model 
included amino acid, dose, pig, time, and replicate. The effects of amino acid, dose, amino 
acid x dose, and replicate were tested with replicate x amino acid x dose as the error term. 
Replicate x amino acid x dose was tested with pig within amino acid x dose x replicate 
as the error term. Time, lime x amino acid, time x dose, and time x amino acid x dose 
were tested with amino acid x dose x lime x replicate as the error term. Differences 
between treatment means within a timc were determined by least-squares contrasts (16). 
In Exp II . data were subjected to the general lincar model split plol-in-lime ANOVA 
( 16), Data were analyzed with pig. treatment. and lime as discrete (class) vari ables. 
Treatment was tested with animal within treatment as the error term. Time and treatment 
x lime were tested with the residual as the error tenn. If a significant treatment x time 
interaclion was detected then differences between treatment means wi thin a specific time 
were determined by least-squares contrasts ( 16). 
In Exp III , data were convened to a percentage of basal secretion before averagi ng to 
minimi ze differences between replicates. To obtain an estimate of variation between 
conlrol wells, medium GH concentrations for control well s were convened to a percentage 
of mean basal GH concentration. This was then used to calcu late an SE for basal secretion. 
Basal secretion (control) was the amount of hormone secreted into the culture medium per 
103 ce lls seeded/well in the absence of a secretagogue. Convened data were tested for 
homogeneity of variance by the use of Han ley's F max test (17). Data were pooled across 
rep licate~ and then subjected to a one-way ANOVA ( 16). Differences between means 
were determined by least-sq uares contrast ( 16). 
RESULTS 
There were no ami no acid x replicate x dose interactions detected in Exp I. Therefore, 
data were pooled across replicates. Amino acid x dose. ami no acid x time, and dose x time 
(P < 0.0 1) interactions were detected. Scrum GH conccntration~ for each amino acid and 
dose are depicted in Figure I. Four of the eight control animals exhibited an endogenous 
GH pulse at approximately 45 min after sali ne treatment. This accounted for the increase 
in GH secretion observed at th is time for control pigs in Figure I . Pretreatment serum GH 
concentrations were similar among groups. All of the ASP doses and the 100- and 150-mg 
doses of GLV increased (P < 0.05) GH secretion by 15 min after treatment when com­
pared wi th the Time 0 GH concentration (Figure 1). The peak GH response was higher (P 
< 0.0 1) for the 100- and 150- mg doses of ASP when compared with the correspondi ng 
doses of GLV (Figure 2). 
In Exp II. the antibcxly titer to GRF. expressed as percent binding at a dilution of 
I:IO,(}()(), was 30.7 ± 1.4% for GRFi pigs and was less than 5% for HSAi pigs when 
expressed as percent binding at a 1: 100 dilution. Serum GH concentrations increased (P 
< 0.05 ) only in HSAi pigs and averaged 1.2 ±.2 nglm l before and 8.2 ± 0.7. 6.3 ± 0.5. 
and 9.2 ± 0.5 nglml by 15 min after 150 mglkg ASP. GLU. or 10 mglkg NMA, respec­
tively (Figure 3). In the NMA-treated pigs, a second increase (P < 0.05) in serum GH 
concentration was observed at 75 min after treatment (Figure 3). This most likely was due 
to a spontaneous GH pulse occause GH concentrations returned to control levels by 45 
min after NMA. 
In Exp 11.1. basa l GH secretion by pituitary cells (lOs cells/well) was 40 ± 6 ng/ml (n = 
14) and GH concentrations increased (P < 0.05) threefold after 10-6 M GRF compared 
with control (Figure 4). Relative to control. GH concentrations increased (P < 0.05) 1.6. 
81.9. and 1.9-fold and 1.7. 1.8, and 2.0-fold after 10- . 10-6. and 10-4 M ASP or GLU. 
respectively (Figure 4). The EAA receptor antagonist AP5 failed to prevent the GH 
response to ASP or GLU. except for 10-8 M ASP (Figure 5). 
mSCUSSION 
The results of this study indicate that both ASP and GLU enhanced GH secretion in the 
prepuberal gi lt. although ASP is a more potent secretagogue of GH secretion than GLU. 
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Figure l. Serum GH cOllCcntracions (mean ± SE) for pigs treated with 0 (conlrol; n :; 8) 50 (n = 6), 100 (n '" 
6), or 150 (n = 6) mglkg BW ASP or OLU. Sample times al which significant effects of treatme rll were detected 
compared with Time 0 are ind icated .•p < 0.05. 
In Exp II, ASP, GLU, and NMA all stimulated GH secretion in mature ovariectomized 
gilts. We previously demonstrated thai Ihe systemic adminiSlr31ion of NMA stimulated 
GH secretion in the mature gilt (9). Moreover, NMA stimulated GH secretion and accel~ 
erated growth in prepuberal monkeys (5) and dramatically increased concentrations of GH 
in gonadectomized male (7) and female (6) sheep. Funher studies are now warranted to 
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Figure 2. Mean (±SE) serum GH concentrations by 15 min aftcr treatmcnt with salitH: (0; n '" 8). 50 (n : 6). 100 
(n :; 6). or 150 mg (n = 6)Jkg BW of ASP or GLU. Column$ with different leuers differ (P < 0.01 ). 
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Figure 3. Serum GH concentrations (mean ± SE) before and after 150 mg/kg BW of ASP. GLU or 10 mg/kg 
BW NMA (Ircatmenl '" Time 0) for pigs immunized against GRFi (n '" 4) or HSAi (n '" 5). Sample times al which 
significant effects of treatme nt were detected arc indica ted .•1' < 0.05. 
test whether the GH response is specific for each EAA and whether EAA plays a phys­
iologic role in the control of GH secretion. 
Acs CI al. (18) reported that NMA failed to increase GH secretion when rals' were 
prelrealed with monosodium glutamate, which resulted in the destruction of hypothalamic 
neurons. Moreover, [rcalmen! wilh the NMA receptor antagonist MK-801 reduced hypo­
thalamic GRF mRNA concentrations ( 19). The failure of exogenou!>ly administered EAA 
or NMA to increase GH secretion in pigs immunized against GRF suppons the idea of a 
eNS site of action. Neural loci at which systemically administered EAA may act to affect 
G H release include the areas of the brain that lack a distinct blood-brain barrier. Price et 
al. (2) demonstrated the preferential uptake of exogcnous ASP or GLU by the circum­
ventricular organs of the rat brain , incl uding the arcuate nucleus. The systemic injection 
of GLU increased GlU levels fourfold in the median eminence, but not in other areas of 
the hypothalamus in mice (3). lbcrefore, EAA might affect GH secretion by influencing 
GRF release from nerve tenninals in the median eminence. 
Alternat ively. the immunoneutrali zation of GRF in this study may have altered the 
pituitary responsiveness to GRF secretion and the subsequent GH response to exoge­
nously administered ASP, GlU, or NMA. [n contrast, Klindt et al. (20) reported that 
viable somatotTOphs were present after hypophyseal !>talk tran!>ection in the pig in the 
absence of hypothalamic stimulatory input. Moreover, hypophyseal stalk-transacted gilt !> 
remained acutely re!>ponsivc to GRF admi nistration. exhibiting a twofold higher GH peak 
release than control animal s (21) . Therefore, it is likely that pitui taries of GRFi pigs 
remained responsive to GRF. 
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in column '" nu mber of wells (Itt ce ll:slwell ) per treatment. Basal secretion (40 ± 6 nglm]) '" control (C). 
Columns with different letters differ (P < 0.05). 
The influence of EAA on GH secretion was observed at all concentrations of the amino 
acids added to porcine pituitary cells in culture. A lack of a dose-dependem response 10 
ASP and GLU and the failure of the EAA receptor antagonist AP5 to reverse stimulation 
by ASP and GLU on GH secrelion suggest a possible nonspecific response rather than a 
response involving specific receptor activation. We previously reported Ihat 10-4 M AP5 
failed to block the NMA-induced release of GH from pig piluitary cell in vitro, although 
Ihi s dose of AP5 antagonized the action of NMA on IUleinizing honnone secretion (10). 
Therefore, it is possible that EAA receptors associated with GH secretion may not be 
antagonized by AP5 or the dose of AP5 used was insufficient to block the effects of ASP 
and GLU. Lindstrom and Ohlsson (22) reported thai NMA stimulaled GH secretion from 
isolaled rat somatotroph~ and that Ihis effeci was blocked by NMA receptor antagonists. 
In conlrm\l, Acs et al. (18) and Caeilovo el al. (19) failed to demonstrate the stimulation 
ofGH secrelion from rat pituitary cells by NMA in culture. The apparent paradox between 
the in vivo and in vi tro results in this study, together with previously published dala, 
indicate that the EAA act at Ihe level of the pituitary and CNS to modulate GH secretion. 
However, the results from Exp 11 suggest that the EAA act primarily at the level of the 
hypOlhalamu~ or higher brain centers 10 release GH, because the EAA-induced release of 
GH was blocked in GRFi gilts. 
GLU and ASP nOI only act as neurotransmitters in the CNS, but also can be used in a 
more nonspecific way as amino acid substrate~. Plasma concentralions of GLU and ASP 
nonnally range between 0.3 and 0.6 mM and 0.03 and 0.1 mM. respectively (23). This is 
comparable to the concentrations of ASP and GLU used in this study. Blood concentra­
tions of GLU and ASP can be altered by pathologic condition (24,25), fasting, and diet 
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Figure 5. Effects of AP5 in combination with ASP or GLU on GH sL"CfCtion after 4 hr of incubation. Values are 
mean ±SE. Number in column = number of wells (Ilf! ce lls/well) per treatment Columns with different lettcrs 
within a Icvel of ASP or GLU differ from ASP or GLU ... AP5 (P -< 0.05). 
(23). It is conceivable Ihal an aheration in the serum concentrations of Ihese amino acids 
could influence GH secretion. In support of this idea. Ihe median eminence, which con­
tains fiber projections from GRF perikarya located in the median basal hypothalamus (26), 
and pituitary gland lie outside of the blood-hrain barrier (27). Therefore, serum concen­
trations of GLU and/or ASP may influence hypothalamic GRF secretion, but also may 
have a direct effect on the pituilary gland. 
In summary, ASP is a more potent secretagogue of GH secretion than GLU in vivo 
although each is equipotent in vitro. Because no stimulation of GH seerelion by EAA was 
observed in ORFi pigs and no dose-response effect of EAA was found in vitro, it is 
concluded that the modulalion of OH secretion by EAA is mediated primarily al the level 
of the hypothalamus or higher brain centers. 
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